Journal of Renal and Hepatic Disorders 2019-10-09T09:39:13+00:00 Scott Bryant Open Journal Systems <p><img style="padding-right: 15px; padding-bottom: 15px; float: left;" src="/public/site/images/jdisord/Jrenhep_logo_png_1001.png">Journal of Renal and Hepatic Disorders (eISSN: 2207-3744) is a peer-reviewed, online-only, open-access journal that publishes basic science and clinical research articles on disorders of the kidneys and the liver. In addition to considering disorders of each organ separately, the journal aims to be a scholarly forum for discussing how disorders of one organ influence the other. Chronic liver disease is associated with primary and secondary kidney diseases. Similarly, renal disorders are associated with hepatic disorders. Original articles, reviews, and case reports on any aspects of nephrology and hepatology are suitable for submission.</p> Hepatitis C Virus Infection and Renal Disorders 2019-10-09T09:39:13+00:00 Maurizio Salvadori Aris Tsalouchos <p>Hepatitis C virus (HCV) infection is frequently associated with extrahepatic disorders, among which renal diseases are frequent. This article highlights the most frequent HCV-associated renal disorders, the impact of HCV infection on chronic renal disease and renal transplantation, and the role of current direct-acting antiviral therapies. HCV is associated with membranoproliferative glomerulonephritis, acceleration of end-stage renal diseases in patients with glomerulopathies, and a higher risk of death in patients affected by chronic kidney disease. Before the introduction of direct-acting antiviral drugs as treatment modality, renal transplantation was a challenging clinical problem because the drugs available until 2011 obtained a poor sustained virologic response, had several side effects, and caused acute rejection when used after transplantation. The knowledge of the viral structure and its replication allowed the discovery of new classes of direct-acting antiviral drugs that revolutionized this scenario. These new drugs are comparatively more effective and safer. Accumulating evidence suggests that it is possible to cure HCV-related glomerulonephritis, and obtain a sustained virologic response in patients with renal failure, or on dialysis, before commencing transplantation. Finally, it became possible to transplant HCV-positive kidneys into HCV-positive or HCV-negative recipients.</p> 2019-01-16T13:25:33+00:00 Copyright (c) 2019 Maurizio Salvadori, Aris Tsalouchos Cholemic Nephropathy: Hyperbilirubinemia and its Impact on Renal Function 2019-10-09T09:38:53+00:00 Jonathan S Chávez-Iñiguez Alejandra Meza-Ríos Arturo Santos-Garcia Guillermo García-García Juan Armendáriz-Borunda <p>Cholemic nephropathy represents a spectrum of renal injury, from proximal tubulopathy to intrarenal bile cast formation, found in patients with severe liver dysfunction. It is caused by hyperbilirubinemia, usually in jaundiced patients. Acute kidney injury is one of the most important complications in patients with end-stage liver disease. The relationship between liver disease and renal impairment, especially the effect of hyperbilirubinemia on renal tissue and renal function, has not been fully elucidated. These considerations deem necessary for nephrologists, when performing a clinical evaluation of patients with liver diseases, for the implementation of an integrated medical approach. This review focuses on the current knowledge on cholemic nephropathy with emphasis on the role of hyperbilirubinemia on renal impairment. The treatment strategies and outcome are also discussed.</p> 2019-03-18T15:25:50+00:00 Copyright (c) 2019 Jonathan Chávez-Iñiguez, Alejandra Meza-Ríos, Arturo Santos-Garcia, Guillermo García-García, Juan Armendáriz-Borunda The Role of Stearoyl-coenzyme A Desaturase 1 in Liver Development, Function, and Pathogenesis 2019-10-09T09:39:07+00:00 Fatemeh Mohammadzadeh Vahid Hosseini Alireza Alihemmati Amir Mehdizadeh Maghsod Shaaker Gholamali Mosayyebi Masoud Darabi <p>Stearoyl-coenzyme A desaturase 1 (SCD1) is a microsomal enzyme that controls fatty acid metabolism and is highly expressed in hepatocytes. SCD1 may play a key role in liver development and hepatic lipid homeostasis through promoting monounsaturated protein acylation and converting lipotoxic saturated fatty acids into monounsaturated fatty acids. Imbalanced activity of SCD1 has been implicated in fatty liver induction, inflammation and stress. In this review, the role of SCD1 in hepatic development, function and pathogenesis is discussed. Additionally, emerging novel therapeutic agents targeting SCD1 for the treatment of liver disorders are presented.</p> 2019-02-06T01:46:15+00:00 Copyright (c) 2019 Fatemeh Mohammadzadeh, Vahid Hosseini, Alireza Alihemmati, Amir Mehdizadeh, Maghsod Shaaker, Gholamali Mosayyebi, Masoud Darabi ADAM and ADAMTS Proteases in Hepatic Disorders 2019-10-09T09:39:00+00:00 Dirk Schmidt-Arras Julia Bolik Janina EE Tirnitz-Parker <p>Proteolysis is an irreversible post-translational modification that regulates protein function and signal transduction. This includes remodelling of the extracellular matrix, release of membrane-bound cytokines and receptor ectodomains, as well as the initiation of intracellular signalling cues. Members of the adamalysin protease subfamily, in particular the ADAM (a disintegrin and metalloprotease) and ADAMTS (the ADAM containing thrombospondin motif) families, are involved in these processes. This review presents an overview of how ADAM and ADAMTS proteins are involved in liver physiology and pathophysiology.</p> 2019-02-07T02:41:40+00:00 Copyright (c) 2019 Dirk Schmidt-Arras, Julia Bolik, Janina EE Tirnitz-Parker Wasting Away with Cirrhosis: A Review of Hepatic Sarcopenia 2019-10-09T09:38:46+00:00 Jan Freeman Andrew Austin Ernesto Robalino Gonzaga <p>The complications of decompensated cirrhosis are well documented and include variceal bleeding, fluid retention, and hepatic encephalopathy. A less well recognized complication of cirrhosis is muscle wasting or sarcopenia. It is now recognized to have a significant impact on patient survival, especially in patients who are awaiting liver transplantation. An understanding of the pathophysiology of muscle protein homeostasis has led to several proposed mechanisms of sarcopenia and the potential to reverse muscle loss. This review discusses the potential mechanisms of sarcopenia and highlights the possible future means of reversing sarcopenia.</p> 2019-09-10T21:25:11+00:00 Copyright (c) 2019 Jan Freeman, Andrew Austin, Ernesto Robalino Gonzaga